Nitroimidazo-oxazole compound DNDI-VL-2098: An orally effective preclinical drug candidate for the treatment of visceral leishmaniasis

by Gupta S, Yardley V, Vishwakarma P, Shivahare R, Sharma B, Launay D, Martin D, Puri SK. Journal of Antimicrobial Chemotherapy 2014, doi:10.1093/jac/dku422.

Summary: Nitroimidazoles are a class of compounds with known antimicrobial activity against various parasites, including kinetoplastids. A selected library of 72 nitroimidazo-oxazoles was evaluated for their anti-leishmanial activity, and led to the identification of DNDI-VL-2098 as a preclinical candidate for further drug development as an oral treatment for VL.

Click here to access the article